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                                    INTRODUCTION 
 
Knowledge of the intraocular manifestations of the leukemia’s and 
lymphomas is important not only because of the frequency with which 
changes are seen but because the eye often reflects the disease state of the 
body. The ophthalmic symptoms may be the initial mode of presentation 
of the systemic illness. Indeed, prior to the use of bone marrow biopsy, 
the ophthalmologist was often called upon to assist with the diagnosis of 
the leukemia’s. 
 Estimates of the frequency of intraocular involvement with 
leukemia range as high as 90% of cases. Although melanoma is the most 
common primary intraocular tumor in adults and retinoblastoma is the 
most common primary intraocular tumor in children, when secondary or 
metastatic neoplastic intraocular disease is considered, intraocular 
manifestations of hematological malignancies are found to be 
overwhelmingly more frequent. 
Reticulum cell sarcoma is the lymphoma that most commonly 
involves the internal structures of the eye. The incidence of neoplastic 
intraocular involvement in patients with the lymphomas is probably much 
less than the incidence in patients with various leukemia’s. The incidence 
of fundus abnormalities associated with anemia or thrombocytopenia 
probably parallels that seen in patients with the various leukemia’s. 
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Almost all the structures in the orbit, adnexiae and eye can be 
involved in lymphoma. Lymphoma of the eye and adnexiae are most 
frequently of B lineage 
Multiple myeloma is a plasma cell neoplasm which can exhibit a 
wide range of systemic and ocular signs and symptoms. Pars plana cysts 
are common and can be a striking ophthalmic finding. Uveal involvement 
has been reported by Bronstein. 
Multiple myeloma is the most common of the plasma cell 
dyscrasias characterized by monoclonal gammopathy and osteolytic bone 
lesions. Ocular involvement in patients with multiple myeloma has been 
well described. The ocular manifestations may be divided into 2 groups: 
those attributable to myeloma infiltration in and about the eye, and the 
ocular consequences of hematologic and serum protein abnormalities. 
Infiltration of the iris has also been reported, simulating a 
nongranulomatous uveitis. A pseudohypopyon can also occur. 
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HISTORY 
In the 1860s, Liebreich first described leukemic retinopathy. Since 
that time, virtually all intraocular structures have been found to become 
involved. 33 different ocular anomalies were listed by Goldbach from 
among the 242 leukemias at John Hopkins Hospital; of this majority are 
seen in the fundus.  
Patients have been reported with leukemic infiltrates of the optic 
nerve, choroid, retina, iris, ciliary body, and anterior chamber.  
In multiple myeloma, Bronstein reported plasma cells floating free 
in the anterior chamber and adhering to the posterior cornea. 
A patient with polycythemia described by Lousea et al. had a one-
and-a-half syndrome from an infarction of the pons. 
In the study performed by Jabaily et al., visual disturbances 
occurred in 6 of 33 patients and included scintillating scotomas, episodic 
dimming of vision, and amaurosis fugax . Murphy et al. reported that 10 
of 37 patients with essential thrombocythemia had visual phenomena as 
part of their disease. Among 33 patients reported by Michiels et al., 10 
had visual symptoms: transient monocular blindness in 3, scintillating 
scotoma in 3, scintillations followed by transient monocular blindness in 
1, and blurred vision in 10  
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         PATHOPHYSIOLOGY OF HAEMATOLOGICAL   
                               MALIGNANCIES                                                          
The leukemia’s are a invariably fatal systemic disease of unknown 
etiology, primarily involving the blood forming organs and characterized 
by widespread, rapid and disorderly proliferation of  the leucocytes and 
their precursors, and by their presence at sometime during the disease of 
immature leucocytes in blood often in large numbers. 
The leukemia’s are often classified according to their type of cell 
that is preponderant in the peripheral blood or in marrow aspirations; they 
may be acute or chronic, and may affect the lymphatic, myeloid, 
monocytic and plasma cell elements. This reduces the field for practical 
purposes to the chronic myeloid and chronic lymphatic leukemia’s (each 
representing a third of the incidence) while the remaining third consists of 
acute leukemia’s (myeloid or lymphatic). In all types males are rather 
more commonly affected than females. 
All types are characterized by moderately uniform enlargements of 
the lymph nodes (esp. the lymphatic group) and of the spleen (esp. the 
myeloid group). Chloroma is a form of acute myeloid leukemia of 
particular ophthalmologic interest since tumor like deposits of leukocytes, 
greenish in colour and locally invasive, form typically in the periosteum 
of the orbit, as well as long bones elsewhere in the viscera and in the 
lymph nodes. The green colour is due to choleglobin, derived from the 
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breakdown product of haemoglobin. Leukosarcoma is the analog of 
chloroma, occurring in ALL. 
The pathologic alterations in all types of leukemia may be divided 
into two types: (a) those that are produced by the proliferation of 
leukemic cells within the blood-forming organs, particularly the bone 
marrow, spleen, and lymph nodes; and (b) those that are produced by 
infiltration of leukemic cells in other organs. Fatigue, pallor, and 
headache ensue. The bone marrow is invariably hyperplastic and reddish 
gray, whereas the degree of cellular proliferation in, with consequent 
enlargement of, the lymph nodes and spleen varies with the different 
types of leukemia. In organs that become infiltrated during the leukemic 
process, it is common to observe destruction of normal tissue and 
replacement by masses of leukemic cells. Organs most likely to be 
affected include the liver, lungs, kidneys, and gastrointestinal tract. 
A variety of mechanisms are responsible for the clinical findings in 
patients with leukemia. A reduction in the normal number of blood-
forming elements may result in anemia, which causes tissue hypoxia, 
ischemia, and infarction; leukopenia, which can result in increased 
susceptibility to infection; and thrombocytopenia, which can lead to 
spontaneous hemorrhage with infarction. Systemic, neurologic, and 
ocular dysfunction may occur from vascular thrombosis caused by the 
tumor cells themselves. Finally, tumor cells may invade the walls of 
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blood vessels, causing hemorrhage and allowing spread of the cells into 
the surrounding tissue. 
         Lymphoma’s represent the most highly differentiated reticulo-
endothelial hyperplasia which results in strictly localized aggregations of 
cells that most nearly resemble normal lymphoid tissue histologically. 
These benign swellings are commonest on the eyelids where they form 
ill-defined spongy tumors that may infiltrate back into the orbit or into the 
lacrimal gland. The symptoms are only due to mechanical 
embarrassment. Ptosis is thus the most common presenting sign, and 
proptosis and diplopia from limited movements, when within the orbit. 
         The cause of multiple myeloma is unknown. One theory is chronic 
antigenic stimulation of a plasma cell, which results in transformation and 
the development of myeloma. However, once a plasma cell is 
transformed, it is known to produce innumerable clones, which spread 
hematogenously to other myelogenous areas. Once there, these neoplastic 
cells form sheets that replace the normal bone marrow. In addition, the 
myeloma cells produce osteoclast-stimulating factor, a cytokine that 
results in bone destruction. The plasma cell activating factor interleukin-6 
(IL-6) is found within bone marrow, resulting in plasma cell proliferation. 
The osteoblastic response in myeloma tends to be suppressed, resulting in 
the severe demineralization and bone destruction that are characteristic of 
the disease. Secondary hypercalcemia is present.                                                             
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                                       OCULAR CHANGES 
               
The ocular changes are predominantly divided into anterior 
segment manifestations and posterior segment manifestations. 
 
ANTERIOR SEGMENT MANIFETATIONS: 
 
Sclera: 
Infiltration of the sclera or episclera by leukemic cells is usually 
found at autopsy and rarely produces any clinical symptoms or signs. The 
cells are most often present in the episclera, with a perivascular 
distribution 
 
Conjunctiva: 
Involvement of the conjunctiva most often occurs in patients with 
lymphocytic leukemia, but it also occurs in other types. Cellular invasion 
occurs at all levels of the substantia propria. It may be diffuse or patchy, 
although it tends to concentrate around blood vessels. In some cases the 
involvement consists of visible nodules with surrounding injection 
resembling areas of focal episcleritis, whereas in others there is only 
slight swelling of the conjunctiva, and in still others there is diffuse and 
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substantial swelling leading to limitation of eye movements. As with 
other ocular manifestations of leukemia, conjunctival involvement may 
occur at any time during the course of the disease and may even be its 
first sign 
The most frequent ocular findings were seen in conjunctiva 
(33.4%) among leukemics in a study in Poland (8). Multiple myeloma is 
one of the causes of a salmon patch conjunctival lesion. 
 
Cornea: 
Because the cornea is normally avascular, direct invasion by 
leukemic cells would not be expected. Leukemia can, however, induce 
formation of a sterile ring ulcer with iritis and pannus . This lesion, also 
called an immune ring, may occur before the diagnosis of leukemia is 
made; therefore, a patient with a corneal ring ulcer should be evaluated 
for leukemia as well as for other causes 
Corneal precipitates have been reported as a complication of 
multiple myeloma for nearly 70 years. Corneal crystals have been 
identified as consisting of immunoglobulins, primarily IgG. Some data 
suggest that elevated immunoglobulin levels in tears or aqueous humor 
lead to corneal crystals, while other data suggest that the 
immunoglobulins reach the cornea through limbal vessels or that 
keratocytes supply the precipitated immunoglobulins(19). In one study, it 
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was seen that Confocal microscopy can enable the clinician to monitor 
the clinical response of multiple myeloma crystalline keratopathy to 
chemotherapeutic agents. It was found that numerous hyperreflective 
globules 6-11 nm in size were located within the corneal epithelium and 
anterior stroma. The development of the crystals can precede systemic 
evidence of multiple myeloma by several years. These crystals obscured 
normal architectural detail of the cornea in multiple myeloma. Lewis et 
al. reported the deposition of copper in both corneas at the level of 
Descemet's membrane in a patient with multiple myeloma and secondary 
hypercupremia. Copper was also deposited in the anterior and posterior 
capsule of the patient's lenses. Dry eye syndrome can occur as a 
manifestation of leukemia  
 
Anterior chamber: 
Anterior chamber leukemic cells and flare,pseudohypopyon and 
hyphema can occur in the anterior chamber. A shallow anterior chamber 
can be present due to iris swelling secondary to leukemic infiltrate.   
Anterior chamber infiltration–simulating hypopyon (pseudohypopyon) 
can occur in multiple myeloma. A pseudohypopyon is characterized by 
its persistence and irregular contour, which suggest clumping of 
neoplastic cellular material rather than the layering of neutrophils, as in 
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anterior uveitis. Bronstein reported plasma cells floating free in the 
anterior chamber and adhering to the posterior cornea (10) 
 
Uvea: 
Cysts of the ciliary body represent the most common ocular 
manifestations in myeloma patients. Infiltration of the iris has also been 
reported, simulating a nongranulomatous uveitis. metastatic carcinomas 
of the iris, which typically appear as solid, amelanotic masses, 
occasionally are discohesive and shed cells that form a hypopyon in the 
anterior chamber (10) 
Infiltration of the anterior segment by leukemic cells occurs rarely 
in patients. It usually occurs in patients with acute leukemia but may also 
occur in patients with chronic leukemia. In some patients, usually 
children, a spontaneous hypopyon-hyphema is the first evidence of the 
disease, whereas in other patients with known leukemia, involvement of 
the iris and anterior segment is the first or only evidence of relapse of the 
disease. The condition is characterized by conjunctival injection, 
symptoms of acute iridocyclitis, and a hypopyon that may be tinged with 
blood. There may be elevated intraocular pressure. Infiltration of the iris 
may be diffuse or nodular. Diffuse infiltration discolors the iris, which 
appears to be covered by a whitish-gray film, and it produces 
hyperchromia or hypochromia iridis when the process is unilateral. If 
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there is nodular infiltration, the nodules are seen over the iris. The 
diagnosis of anterior segment involvement by leukemia can be confirmed 
by paracentesis with cytologic examination of the aqueous humor. The 
condition can be treated effectively with low-dose irradiation to the 
anterior portion of the globe. 
The choroid is commonly infiltrated by leukemic cells during the 
course of both acute and chronic leukemia. In fact, Leonardy et al. found 
the choroid to be the most frequently involved site (31.1%) of ocular 
involvement in an autopsy series of leukemic patients. Abnormalities that 
are visible during ophthalmoscopy, however, are rare. Nevertheless, some 
patients develop generalized serous detachment of the retina, retinal 
pigment epithelium, or both, associated with diffuse infiltration of the 
choroid by leukemic cells. Others develop localized choroidal masses 
with overlying retinal and RPE detachment, and rare patients develop 
pigmentary changes in the RPE from interference of the blood supply to 
the RPE by leukemic cells that infiltrate the choroid  
 
Neuro-ophthal manifestations: 
Third nerve palsy, lower facial nerve palsy and 6th nerve palsy 
have been reported. 
CLL can present with acute optic neuropathy associated with 
cerebrospinal fluid evidence of meningeal spread of malignant cells (12). 
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Visual loss in myeloma is usually caused by compression or 
infiltration of the optic nerves by tumor (13).  
The mechanism of optic neuropathy in this case is probably related 
to infiltration of the optic nerve meninges by malignant plasma cells and 
impaired vascular supply caused by aggregated intraluminal plasma cells 
and monoclonal hypergammaglobulinemia (14). 
In one study, neuro-ophthalmic symptoms resulting in diplopia or 
visual disturbances were reported (21). 
         Neurological complications of leukemia are caused by a variety of 
different processes. First, neurologic injury may be caused by leukemic 
invasion of the leptomeninges, parenchyma, spinal cord, nerve roots, and 
peripheral nerves. Second, leukemia may cause cerebrovascular 
disorders, both hemorrhagic and ischemic, by obstructing intracranial 
vessels. Third, neurologic sequelae may result from the various forms of 
treatment of the disease. Fourth, some neurological disorders in patients 
with leukemia are paraneoplastic. In most cases, however, leukemic 
involvement of the CNS occurs from hematogenous spread or by direct 
invasion from adjacent affected bone marrow. 
CNS leukemia is diagnosed by cerebrospinal fluid (CSF) analysis, 
requiring a minimum of five white blood cells per microliter and the 
presence of leukemic blast cells by cytospin technique.  
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Since the advent of successful therapy of leukemia, the meninges 
have become the major site of leukemic relapse. With the advent of 
intrathecal chemotherapy and cranial irradiation as routine CNS 
prophylaxis, the incidence of meningeal leukemia has declined to 
approximately 10%. For those who suffer meningeal involvement 
following radiation therapy, however, prognosis is poor. Meningeal 
involvement occurs more commonly in acute lymphoblastic leukemia 
than in acute myeloblastic leukemia and is rare in the chronic 
lymphocytic leukemias . 
Meningeal leukemia occurs when the meninges are infiltrated by 
leukemic cells from the arachnoid veins. These cells then enter the CSF, 
including the Virchow-Robin spaces, penetrate the pia-glial membrane, 
and may invade brain parenchyma. On histopathology, the meninges 
show diffuse and focal invasion of leukemic cells, often in a perivascular 
configuration. Meningeal leukemia may produce a variety of symptoms 
from single as well as multiple cranial neuropathies and may also cause 
increased ICP. Affected patients may thus develop headache, 
meningismus, nausea, vomiting, papilledema, increasing lethargy, and 
focal neurologic signs, including diplopia from ocular motor nerve 
paresis. Papilledema occurs in up to 50% of such patients. The cranial 
sutures may be split in young children. Cranial neuropathies may result 
from infiltration of leukemic cells or from compression. Among the most 
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commonly involved are those with neuro-ophthalmologic impact, 
including the optic nerve, the oculomotor nerve, and the abducens nerve . 
Facial and vestibulocochlear neuropathies are also common, and the 
lower cranial nerves are occasionally affected. 
In most cases, leptomeningeal and parenchymal infiltration occurs 
at a relatively late stage of the disease after the diagnosis is established, 
but this is not always the case. In a series of 30 children with neurological 
presentations of malignancy, one-third had acute leukemia. Papilledema 
and ocular motor neuropathies may be presenting manifestations of acute 
lymphocytic leukemia. 
Leukemic involvement of the brain parenchyma is usually an 
extension of meningeal infiltration, but rare autopsy results document 
isolated leukemic parenchymal collections. These may be the result of a 
mechanism other than invasion from the meninges or from treatment that 
suppresses meningeal leukemic cells but spares those deep within the 
parenchyma. Parenchymal involvement is usually perivascular. More 
diffuse infiltration may be seen in hypothalamic presentations with 
symptoms of hyperphagia, obesity, and somnolence. Rarely, discrete 
tumor nodules are found. Rarer are chloromas, also called granulocytic 
sarcomas and myeloblastomas. These are collections of immature 
myeloid cells that are more common in the chronic form of the disease 
and that may also be seen in myeloproliferative disease. They may 
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precede the onset of leukemia, be a harbinger of transformation from 
chronic to acute forms, or signal a relapse. Chloromas are usually single, 
but they may be multiple. They may arise in various locations in the CNS 
parenchyma and dura. They are isointense to white matter on magnetic 
resonance (MR) T1- and T2-weighted images and are isointense to 
hypointense on computed tomographic (CT) imaging, enhancing with 
contrast. 
Leptomeningeal infiltration can lead to infiltration of the 
intracranial portions of the optic nerves and optic chiasm. In most 
patients, visual loss may be slow and progressive, responding to radiation 
therapy, or extremely rapid. Cerebrovascular disorders may produce 
neurological dysfunction in patients with leukemia. The majority is 
hemorrhagic, caused by invasion of blood vessel walls by leukemic cells, 
thrombocytopenia, sepsis, and disseminated coagulopathy. Blast crisis, 
extreme leukocytosis, and thrombocytopenia are predisposing factors. 
Intracranial hemorrhage contributes to mortality in 10 to 21% of leukemic 
patients. Cerebral ischemia is less common than hemorrhage and may 
result from arterial or venous obstruction. In leukemic patients, cerebral 
venous thrombosis is the most common form of infarction, resulting in 
focal neurologic deficits, increased ICP, and papilledema. Arterial 
infarction may involve large vessels, cause lacunar events, or result from 
septic emboli. 
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Patients with leukemia may develop neurological dysfunction from 
the toxic effects of drugs used to treat the leukemia and from infections 
that occur in the CNS of patients who are debilitated or 
immunosuppressed. With conventional cranial radiotherapy, 
neurotoxicity is more often subacute and delayed, rather than acute. 
Intrathecal methotrexate may cause chemical meningitis. A subacute 
leukoencephalopathy occurs in patients treated with methotrexate and is 
thought to be caused by direct toxicity of the drug. It is more commonly 
encountered when methotrexate is given in high doses intravenously and 
intrathecally and/or combined with cranial irradiation, and it occurs in up 
to 50% of children undergoing such therapy. Other drugs may produce a 
similar encephalopathy, a peripheral neuropathy, or both. 
Neurological disturbances in patients with Hodgkin's disease may 
result from involvement of the intracranial portion of the CNS, the spinal 
cord, or the peripheral nervous system (PNS). According to some authors, 
involvement of the nervous system in patients with Hodgkin's disease 
occurs in 13 to 15% of all cases , although a review of 2,185 patients with 
Hodgkin's disease found only 12 (0.5%) who developed neurological 
symptoms, signs, or both . This discrepancy may be related to 
increasingly early diagnosis and treatment of this condition. Most 
examples of neurological involvement are secondary, occurring from 
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discrete or diffuse metastases via meningeal vessels or from direct tumor 
extension. 
When involvement of the meninges is primarily intracranial, single 
or multiple cranial neuropathies with and without papilledema commonly 
occur. In addition, single or multiple tumor nodules may implant on the 
meninges and enlarge, ultimately compressing and invading the substance 
of the brain and producing focal neurological defects. 
Single or multiple intracranial masses may develop in patients with 
systemic Hodgkin's disease. These lesions may be located anywhere 
within the cranial vault. In such cases, the symptoms and signs are related 
to the location and size of the lesion. They include focal or generalized 
seizures, focal neurological signs, confusion, mental deterioration, and 
coma. Visual disturbances in such cases include visual hallucinations, 
unilateral or bilateral visual loss from invasion of the optic nerves, visual 
field defects indicating chiasmal dysfunction, or homonymous 
hemianopic field defects from damage to the postchiasmal visual sensory 
pathway. A cavernous sinus syndrome with multiple cranial nerve pareses 
may occur, but diplopia and ptosis may also result from invasion of the 
brainstem and disruption of the cranial nerve nuclei or their fascicles. 
Peripheral neuropathy affects some patients with Hodgkin's disease. 
Patients with Hodgkin’s disease can also have Horner syndrome from 
damage to the oculosympathetic pathway or paralysis of the diaphragm 
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from damage to the phrenic nerve. As is the case with CNS dysfunction, 
involvement of the PNS is usually a secondary phenomenon in patients in 
whom systemic Hodgkin's disease has previously been diagnosed. 
Evidence of central (and occasionally peripheral) nervous system 
dysfunction in patients with Hodgkin's disease generally appears late in 
the course of the disease. Nevertheless, such dysfunction may occur as 
the initial and only manifestation of the process, months or years before 
any other evidence of Hodgkin's disease appears. 
In some instances, a patient has constitutional symptoms or 
laboratory evidence compatible with Hodgkin's disease, but the diagnosis 
is not suspected until the CNS lesion is biopsied or, if that lesion is 
incorrectly diagnosed, not until months or even years later. This is 
particularly true when visual loss is the primary disturbance. In addition 
to visual loss from damage to parts of the visual sensory pathway and 
diplopia from damage to the ocular motor nuclei, fascicles, and nerves, 
Hodgkin's disease may produce visual symptoms from involvement of 
ocular structures, although this is uncommon. Ocular abnormalities 
associated with Hodgkin's disease include uveitis and retinopathy, 
keratitis sicca with bilateral enlargement of the parotid glands, and 
keratitis with vascularization. Siatkowski et al. reported a 21-year-old 
man who developed a left optic neuropathy associated with ipsilateral 
orbital pain after being in clinical remission of Hodgkin's disease for 2 
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years. The left optic disc showed moderate swelling with a few 
peripapillary hemorrhages. MR imaging showed diffuse enhancement of 
the nerve following intravenous administration of gadolinum-DTPA. The 
CSF was under normal pressure, had a normal concentration of protein 
and glucose, and contained no cells on standard or cytopathologic 
examination. Because of the suspicion of lymphomatous infiltration of 
the optic nerve, the patient was treated with 2000 cGy radiation, 
intravenous methylprednisolone, and oral prednisone. Over the next 6 
weeks, vision improved, and the disc swelling resolved. Biopsy of a 
cervical lymph node revealed evidence of recurrent Hodgkin's disease. 
Patients with Hodgkin's disease (and patients with other lymphomas) may 
develop neurologic dysfunction, visual dysfunction, or both from 
paraneoplastic disorders. These disorders, which include encephalitis, 
encephalomyelitis, cerebellar degeneration, peripheral sensory and motor 
neuropathies, acute and chronic dysautonomia, cancer-associated 
retinopathy, and optic neuropathy, occur in a wide variety of 
malignancies and are thought to be caused by immune-mediated remote 
effects of the cancer. Kay et al.  Reported a patient who developed 
opsoclonus-myoclonus syndrome after treatment of Hodgkin's disease by 
chemotherapy and autologous bone marrow transplantation. These 
authors speculated that chemotherapy resulted in breakdown of 
lymphomatous tissue and the production of antineuronal antibodies. A 
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patient described by Abrey  developed myasthenia gravis characterized 
by ptosis, diplopia, generalized weakness, and dysphagia in the setting of 
extrathymic Hodgkin's disease. When the Hodgkin's disease was treated 
with antineoplastic therapy, the myasthenia gravis completely resolved, 
suggesting a paraneoplastic etiology. 
Neurological dysfunction in patients with multiple myeloma may 
be caused by compression of neural tissue by single or multiple tumors or 
by displaced bone; meningeal dissemination with infiltration of neural 
tissue by tumor cells; systemic complications of the disease (e.g., 
metabolic or hematologic disturbances, infection); and complications of 
therapy for multiple myeloma rather than from the disease itself. 
The neural structure most susceptible to compression is the spinal 
cord. Compression of the spinal cord may occur from an extradural 
plasmacytoma that originates within one or more of the vertebral bodies 
or in the epidural space. Compression may also occur from the effects of 
a plasmacytoma within the subdural or subarachnoid space. Neural 
structures other than the spinal cord may be compressed by myeloma 
cells or adjacent, diseased bone. These structures include the spinal nerve 
roots, the cranial nerves, and the brain parenchyma. 
When spinal nerve roots are compressed, patients develop a 
radiculopathy that may be characterized by motor signs, sensory changes, 
and abolition of deep-tendon reflexes. Not all cases of polyneuropathy are 
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associated with evidence of nerve root compression, however. Some 
appear to be paraneoplastic, i.e., related to a secondary or distant effect of 
the myeloma. 
Cranial neuropathy occurs less frequently in patients with multiple 
myeloma than does spinal cord or nerve root compression. Nevertheless, 
almost any cranial nerve may be affected, either in isolation or in 
combination with other cranial nerves. In some cases, there is associated 
lethargy and a generalized decrease in the level of consciousness from 
diffuse meningeal involvement by myeloma cells. 
Intracranial plasmacytomas, either in the setting of multiple 
myeloma or as isolated lesions in patients with no systemic evidence of 
multiple myeloma, may produce a variety of focal neurologic signs from 
compression of adjacent brain tissue, or they may cause increased ICP 
from a generalized mass effect or from obstruction of the dural venous 
sinuses. In most cases, the brain is involved by extension of the tumor 
from the calvarium, the dura overlying the cerebral and cerebellar 
hemispheres, or the falx cerebri; however, in rare instances, there are 
solitary or multiple plasmacytomas that have no osseous or dural 
component. It is in such cases that systemic evidence of multiple 
myeloma is least likely to be found, and treatment is usually directed 
toward surgical removal of the lesions followed by radiation therapy. 
Multiple myeloma may infiltrate neural tissue as well as compress it. This 
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is particularly true with regard to cranial neuropathies; however, 
infiltration without evidence of a mass lesion may also occur in brain 
parenchyma.  
Patients with multiple myeloma develop a peripheral neuropathy 
which may be sensory, motor, or mixed sensorimotor type. When it is 
purely sensory, patients complain of numbness, pain, or both; when it is 
purely motor, it is characterized by slowly progressive, painless weakness 
of the extremities. Patients with the mixed sensorimotor type of 
peripheral neuropathy experience slowly progressive distal numbness, 
hypesthesia, and weakness, usually affecting the legs more than the arms. 
Nerve conduction studies are abnormal in all cases, regardless of the type 
of peripheral neuropathy. In some cases, the peripheral neuropathy is 
related to systemic amyloidosis or a sclerotic form of multiple myeloma; 
however, in most cases there is no evidence of either compression or 
infiltration of the involved neural tissue nor is there any evidence that the 
process is related to the metabolic or hematological effects of the disease. 
It may be present before the diagnosis of multiple myeloma, and its 
course is usually independent of the course of the myeloma. The 
neuropathy thus bears close resemblance to the carcinomatous 
neuropathies that occur as paraneoplastic phenomena associated with 
certain types of systemic malignancies and are thought to be autoimmune 
in origin. Indeed, in about 40% of patients with peripheral neuropathy 
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associated with multiple myeloma or one of the other monoclonal 
gammopathies, IgM reacts with myelin or with the intermediate filament 
vimentin that is found in high concentrations in Schwann cells. Finally, 
the therapy of multiple myeloma may also produce neurological 
dysfunction. 
Because of its proximity to the base of the skull and its long 
extradural course, the abducens nerve is the cranial nerve most commonly 
affected by multiple myeloma, and it is also commonly involved by 
plasmacytomas located at the base of the skull. The dysfunction may be 
unilateral or bilateral. It may be isolated, or it may occur in association 
with other cranial neuropathies, including optic neuropathy. Cranial 
nerves other than the abducens nerve, including the vestibulocochlear and 
trigeminal nerves and the other ocular motor nerves, can be damaged by 
multiple myeloma and plasmacytomas. As with abducens nerve paresis, 
paresis of the oculomotor or trochlear nerves that occurs in these settings 
can be isolated or associated with other neurological abnormalities. The 
paresis may be the first sign of the disease, or it may occur late in the 
course of the disease. Rare cases of ocular motor nerve paresis are 
bilateral, thus mimicking an intrinsic brainstem process, but most are 
unilateral. 
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Orbit: 
Orbital infiltrarions are reported in leukemia. Orbital 
plasmacytoma can be the first manifestation in certain cases of multiple 
myeloma (20). 
All types of leukemia may involve the orbit; however, such 
involvement occurs more frequently in acute leukemia than in chronic 
leukemia. Leukemia is therefore a not infrequent cause of proptosis in 
children. Various authors report that 2 to 11% of children with proptosis 
have some form of acute leukemia. The orbital involvement may be 
related to infiltration of soft tissue by leukemic cells, to hemorrhage, or to 
both. 
Orbital infiltration in leukemia causes proptosis, diplopia, edema of 
the eyelids, chemosis of the conjunctiva, and moderate to severe pain, 
thus mimicking an orbital cellulitis. It usually occurs in patients with 
previously diagnosed leukemia, but in some cases, it is the first evidence 
of the disease. 
Leukemic cells may infiltrate almost all of the structures in the 
orbit, including the extraocular muscles, fat, and lacrimal gland. 
Leukemic infiltration may even extend beyond the confines of the orbit 
into the paranasal sinuses. It is usually diffuse, but in some patients, the 
infiltration produces a relatively well-circumscribed mass of leukemic 
cells. Although such a mass can accompany any form of leukemia and 
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can be observed in patients with chronic leukemia after long periods of 
remission, it occurs most often in patients with acute myelogenous 
leukemia. In such patients, the mass may have a characteristic greenish 
appearance caused by the pigmented enzyme myeloperoxidase and is 
called, as noted above, a granulocytic sarcoma or chloroma. The cause of 
granulocytic sarcoma is unknown, but cellular immune deficiency may 
play an important role. Granulocytic sarcomas may appear at any time 
during the course of the leukemia and, like diffuse infiltration, may even 
occur months or even years before there is any evidence of other systemic 
disease. In patients with leukemia, bilateral involvement of the orbits is 
not uncommon. It is usually a poor prognostic sign  
Granulocytic sarcoma or chloroma is an unusual localized tumor 
composed of cells of myeloid origin. Involvement of the orbit and the 
ethmoid sinuses and presenting as proptosis is rare (22). 
Orbital involvement is a rare complication of Hodgkin's disease. 
The majority of cases occurs in patients with known Hodgkin’s disease 
and consists of infiltration of the eyelids, subconjunctival space, 
conjunctiva, soft tissues of the orbit, and lacrimal gland. In some Patients 
with multiple myeloma may develop signs of an orbital process as the 
result of their myeloma. Such patients may present with proptosis, 
diplopia, visual loss, or a combination of these manifestations. Eye, brow, 
or orbit pain may be a prominent complaint, although this is by no means 
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always the case. Some of these patients have multiple myeloma at the 
time their orbital symptoms and signs develop, but in most, the orbital 
process is the first sign of the disorder. In these patients, myeloma cells 
usually infiltrate orbital soft tissue. The infiltration is often diffuse, 
affecting all of the tissues in the orbit, including fat, extraocular muscles, 
and lacrimal gland, but it also may be limited, presenting as focal 
enlargement of the lacrimal gland or as a well-defined mass. Orbital 
involvement is usually unilateral, but it may be bilateral. In rare cases, the 
orbital disease is not caused by infiltration by myeloma cells per se but by 
amyloidosis, which may occur in patients with multiple myeloma and is 
usually homologous with portions of the immunoglobulin light chains 
that are produced in abundance as a consequence of the disease. 
As is the case with intracranial disease, some patients have a 
solitary plasmacytoma within the orbit unassociated with any systemic 
evidence of multiple myeloma. It is important to remember, however, that 
although such patients may have no evidence of systemic multiple 
myeloma at the time that the orbital lesion becomes apparent, only long-
term observation can truly establish if the lesion is a benign, localized 
collection of  
Plasma cells or an early manifestation of systemic multiple 
myeloma. Involvement of the orbit is the first sign of the disease in a few 
cases. 
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Opportunistic infections:  
 Bilateral herpes simplex dendritic corneal ulcer and herpes zoster 
vesicles can occur. Pseudomonas panophthalmitis causing scleral and 
corneal melt. Branhamella catarrhalis corneal ulcer can progress to 
phthisis bulbi can also occur (9). 
Bilateral endogenous Fusarium endophthalmitis as the initial 
manifestation of a disseminated infection in a patient with hematological 
malignancy (18) 
Patients with AIDS are at higher risk for developing Hodgkin's 
lymphoma. As in patients without AIDS, the disorder may present with a 
variety of manifestations.  In patients with AIDS, orbital and sinus 
involvement can be the initial presentation of Hodgkin's disease. 
The neurological and visual dysfunctions that occur in patients 
with Hodgkin's disease are not always related to the direct effects of the 
disease. Some patients with Hodgkin's disease develop infections or 
inflammations related to their debilitated and often immunosuppressed 
state. These include cryptococcal meningitis, aspergillosis, cytomegalic 
inclusion disease, herpes zoster, PML, and granulomatous angiitis of the 
CNS. 
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POSTERIOR SEGMENT MANIFESTATIONS 
The posterior segment manifestations of haematological 
malignancies can be divided into1) direct manifestations (leukemic 
infiltrates), 2) possible direct manifestations (such as white-centered 
retinal hemorrhages), 3) manifestations of complications of malignancy 
(chiefly anemia, thrombocytopenia, and hyperviscosity states) and 4) 
opportunistic infections. Finally, there may be5) chance or unrelated 
findings. 
Multiple myeloma is a neoplasm of plasma cells producing an 
excess of one type of immunoglobulin. The main ocular features are those 
araising from the local orbital/intracranial presence of the osteolytic 
lesions or from the effect of increased viscosity with retinal haemorrhages 
/ vascular occlusion. 
 
Retinal or preretinal infiltrates: 
 Leukemic infiltrates have been described by Kuwabara.  A patient 
with chronic myelogenous leukemia with large gray-white nodules of 
varying sizes in the retina was reported. Gray-white streaks along vessels 
may be caused by perivascular leukemic infiltrates. Infiltrates are also 
observed in the retina in systemic lymphomas also. 
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Choroidal infiltrates: 
 Although the choroid is probably the most commonly affected part 
of the eye in leukemia’s, clinical signs of choroidal involvement are often 
subtle unless there is overlying retinal changes which bring them to 
attention. Serous retinal detachment overlying choroidal infiltrates or 
overlying frank choroidal masses are important clues. Serous retinal 
detachment overlying areas of choroidal infiltration have been reported in 
patients with CLL, ALL, CML and AML. Serous retinal pigment 
epithelial (RPE) detachment has also been reported in a patient with acute 
lymphoblastic leukemia. The serous retinal and RPE detachments can be 
the presenting manifestation of the leukemia. Eventually, as the changes 
resolve, coarse clumping of the RPE is seen. Areas of RPE hyperplasia 
including heaped-up masses of pigment epithelium surrounding leukemic 
cells. 
The choroid is commonly infiltrated by leukemic cells during the 
course of both acute and chronic leukemia. In fact, Leonardy et al. found 
the choroid to be the most frequently involved site (31.1%) of ocular 
involvement in an autopsy series of leukemic patients. Abnormalities that 
are visible during ophthalmoscopy, however, are rare. Nevertheless, some 
patients develop generalized serous detachment of the retina, retinal 
pigment epithelium, or both, associated with diffuse infiltration of the 
choroid by leukemic cells. Others develop localized choroidal masses 
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with overlying retinal and RPE detachment, and rare patients develop 
pigmentary changes in the RPE from interference of the blood supply to 
the RPE by leukemic cells that infiltrate the choroids 
 
Vitreous infiltrates: 
 Vitreous opacities may be manifestations of an intraocular 
malignancy. Moribund patients may show massive collections of tumor 
cells in the vitreous, but most patients with intravitreal hemorrhage have 
neoplastic cells in the vitreous only because their peripheral blood 
contains tumor cells. The cells do not appear to be preferentially 
replicating in the vitreous cavity. 
 Leukemic cells have been found in the vitreous of patients with 
neovascularization of the disc. Disc neovascularization has also been seen 
in a patient with erythroleukemia although that patient also had diabetes. 
Vitreous involvement has been seen at the time of autopsy in patients 
with reticulum cell sarcoma, Burkitt's lymphoma, multiple myeloma, and 
Hodgkin's disease 
In leukemia the internal limiting membrane usually acts as a barrier 
to infiltration of the vitreous by leukemic cells; however, such infiltration 
occasionally occurs. Terson syndrome occurs in rare cases. 
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White-centered retinal hemorrhages (Roth spots):  
Most patients are asymptomatic or have visual loss related to the 
underlying disease process. White-centered retinal hemorrhages may be 
isolated or more numerous, 
Depending on the association. White-centered hemorrhages most 
likely result from 
Localized capillary rupture from any anoxic insult or sudden 
elevation in venous pressure. The white center is a fibrin platelet 
aggregate that results during the physiologic 
Healing process. The collections of abnormal white blood cells 
(leukemia/lymphoma) or platelets (multiple myeloma). The most 
common underlying factors are anemia and thrombocytopenia.  
 
Manifestations of anemia and thrombocytopenia: 
 Leukemic retinopathy is the term most often used to denote the 
fundus manifestations of anemia, thrombocytopenia, and increased blood 
viscosity seen in patients with leukemia. In general, the term does not 
necessarily refer to frank leukemic proliferation. The changes of 
"leukemic retinopathy" may be more commonly seen with the acute 
leukemias but the frequency with which they occur has not been 
adequately studied to be certain. Although perivascular sheathing may be 
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due to actual perivascular infiltrates, tortuous dilation of the retinal veins 
probably is not. The veins and arteries may assume a yellowish tinge both 
because of anemia and leukocytosis. Retinal hemorrhages may be seen, 
often at the posterior pole. The hemorrhages may be subretinal, deep 
retinal, superficial retinal, or preretinal, and there may be breakthrough 
bleeding into the vitreous cavity. They may have a blot or blotch shape, 
flame shape, or they may have white centers. 
 Cotton-wool spots may be the presenting abnormality that 
precipitates the systemic evaluation leading to the diagnosis of leukemia. 
The cotton-wool spots may be due to local factors, such as an abnormally 
large cell or cluster of cells occluding retinal arterioles, and may not be 
related to the overall peripheral blood composition. In general, 
hematologic parameters are not associated with the presence of cotton-
wool spots. Cotton-wool spots and hemorrhages can resolve in patients 
with chronic disease. 
Retinal hemorrhages and cotton-wool spots related to anemia or 
thrombocytopenia are common in patients with non-Hodgkin's 
lymphoma, but direct retinal involvement of the retina in patients with 
systemic lymphoma is extremely rare.  Hodgkin’s disease can cause 
periphlebitis, focal chorioretinitis, vitreitis, and optic disc edema Patients 
with "numerous white deposits in the retinal periphery," chorioretinitis, 
Roth's spots, and perivascular retinitis have been reported 
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In multiple myeloma the most common retinal findings include 
manifestations of anemia and thrombocytopenia such as flame-shaped or 
white-centered hemorrhages and nerve fiber layer infarcts.  
 
Manifestations of hyperviscosity: 
 Whole-blood hyperviscosity may lead to veno-occlusive disease, 
microaneurysm formation, retinal hemorrhages, and retinal 
neovascularization. The most common manifestation is probably a mild 
or "hyperpermeable" central retinal vein occlusion. A systemic 
hyperviscosity state should be suspected in patients with bilateral 
changes. Peripheral retinal neovascularization has been reported in 
patients with CML in association with peripheral capillary nonperfusion. 
Most cases have associated extreme leukocytosis or thrombocytosis. 
Presumably, the hyperviscosity state leads to peripheral nonperfusion and 
subsequent development of retinal neovascularization.In general, the 
blood viscosity begins to increase remarkably only with white blood cell 
counts of greater than 50,000. 
In multiple myeloma Increased viscosity results in reduced flow of 
blood through the eyes and produces the characteristic changes of 
dilataion of the retinal arteries and veins, hemorrhages, microaneurysms 
and areas of capillary closure. 
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Microaneurysm formation may be apparent, most frequently in the retinal 
periphery and mid periphery. If hyperviscosity is severe, retinal changes 
similar to those described in Waldenström's macroglobulinemia may be 
seen. Serous and exudative retinal detachments associated with multiple 
myeloma have also been reported. Reduction in the abnormalities 
producing hyperviscositoes can reverse retinal changes. 
 
Optic Neuropathy: 
Visual loss in myeloma is usually caused by compression or 
infiltration of the optic nerves by tumor. Bilateral optic disc swelling can 
be the initial clinical manifestation of multiple myeloma. The mechanism 
of optic neuropathy is probably related to infiltration of the optic nerve 
meninges by malignant plasma cells and impaired vascular supply caused 
by aggregated intraluminal plasma cells and monoclonal 
hypergammaglobulinemia. 
Optic nerve head infiltration with acute lymphoblastic leukemia 
has also been described 
In the past, leukemic infiltration of the orbital portion of the optic 
nerve (like that of the intracranial portion) occurred in the late stages of 
the disease, usually as a preterminal phenomenon. Since the advent of 
sophisticated chemotherapeutic regimens and the use of prophylactic 
CNS irradiation in the treatment of leukemia, the prognosis for long-term 
35 
 
survival has improved so dramatically that leukemic invasion of the optic 
nerve is not uncommon and should be considered a treatable cause of 
vision loss. Clinical evidence of infiltration of the orbital portion of the 
optic nerve occurs primarily in children and adults with acute leukemia, 
especially those with the acute lymphocytic variety. Histopathologically, 
however, optic nerves from patients with acute leukemia are only slightly 
more likely to show evidence of leukemic infiltration than are nerves 
from patients with chronic leukemia. Although active bone marrow 
disease as well as involvement of the CNS is usually present at the time 
the infiltration becomes evident, optic nerve infiltration may be the first 
manifestation of recurrence leukemia or relapse. 
Leukemic infiltration of the optic nerve may produce two distinct 
clinical patterns. In one pattern, the prelaminar and laminar portions of 
the optic nerve are infiltrated; in the second pattern, the infiltration is 
retro laminar. Infiltration of the optic disc occurs less frequently than 
does retrolaminar infiltration. 
When the optic disc is infiltrated, the appearance is that of a fluffy, 
whitish infiltrate within the substance of the disc. The infiltrate is usually 
associated with disc swelling and hemorrhage. In this setting, the visual 
acuity is usually normal or only minimally reduced, although if the 
infiltration, swelling, or hemorrhage extend into the macula, significant 
impairment of central vision may occur. 
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Leukemic infiltration of the retrolaminar portion of the optic nerve 
is associated with a variable degree of optic disc swelling. The fluffy 
appearance that is characteristic of optic disc invasion is absent in such 
cases, but an associated retinopathy that includes evidence of both arterial 
and venous occlusion may be present. Although leukemic infiltration of 
the retrolaminar portion of the optic nerve may be compatible with 
normal visual function, there is usually moderate to severe loss of vision. 
Because both patterns of leukemic infiltration of the optic nerve are 
associated with some degree of optic disc swelling, they must be 
differentiated from papilledema. In many cases, this is extremely 
difficult, not only because in all three settings there is optic disc swelling 
associated with minimal if any visual loss, but also because it is not 
unusual for optic nerve infiltration to occur simultaneously with 
meningeal infiltration and increased ICP , particularly in the setting of 
treatment of acute promyelocytic leukemia with all-trans retinoic acid . 
For this reason, in all patients who present with optic disc swelling in the 
setting of leukemia, neuroimaging studies and a lumbar puncture must be 
performed. Both CT scanning and MR imaging typically show 
generalized enlargement of the affected optic nerve often associated with 
a cuff of enhancement surrounding the nerve that represents leukemic 
cells. Ocular echography may also be helpful in this setting, showing that 
the nerve itself is enlarged. 
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The treatment of leukemia is discussed below; however, it is 
appropriate here to emphasize that the optimum treatment for infiltration 
of the optic nerve is prompt local irradiation. This is typically performed 
urgently and followed by intrathecal as well as systemic chemotherapy. 
Patients who receive about 2000 cGy to the posterior globe and orbit 
usually show a rapid resolution of their disc swelling and infiltration that 
may be accompanied by improvement in vision. 
In addition to infiltration, neovascularization of the optic disc 
occurs in patients with acute leukemia, particularly the lymphocytic type 
An optic chiasmal syndrome may be produced by a plasmacytoma that 
mimics a pituitary adenoma. Homonymous field defects in patients with 
multiple myeloma may result from compression or infiltration of the 
postchiasmal visual sensory pathways by myeloma cells, from secondary 
effects of the disease (e.g., infarction of the occipital lobe), or from 
infectious complications of the disease, its therapy, or both (e.g., 
intracranial abscess formation 
 
Vascular Occlusions: 
Visual disturbances in patients with essential thrombocythemia are 
related to thrombotic, hemorrhagic, and possibly vasomotor phenomena. 
For example, patients may experience embolic retinal artery occlusions, 
amaurosis fugax, or CRVO.  
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The ocular abnormalities seen in patients with polycythemia vera 
are similar to those seen in patients with other hyperviscosity syndromes. 
Their severity is related to that of the polycythemia and its duration. 
Many patients develop engorgement of the conjunctival and retinal 
vessels. The associated ischemic disorders of the eye may become 
manifest as dilated, tortuous vessels, retinal hemorrhages, central retinal 
artery occlusion (CRAO), central retinal vein occlusion (CRVO), and 
anterior ischemic optic neuropathy (AION). CRVO may be bilateral. As 
mentioned above, papilledema may result from the effects of thrombosis 
of the cerebral venous sinuses. Optic disc swelling may also result from 
local vascular changes related to hyperviscosity 
Patients with multiple myeloma often have retinal vascular 
abnormalities that appear to be related not to infiltration of the eye by 
myeloma cells but to the hyperviscosity that accompanies the systemic 
disease. The increased viscosity leads to reduction in blood flow in the 
retina and secondary ischemia. In the early stage of the disease, the main 
changes are in the veins, which become dilated and somewhat tortuous. 
As the process progresses, these vessels show segmentation with sausage-
like dilations and constrictions. Progression produces intraretinal 
hemorrhage, exudation, and microinfarcts (cotton-wool spots). 
Eventually, the patient may suffer a branch retinal vein occlusion or a 
CRVO that may be unilateral or bilateral. Rarely, retinal findings presage 
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the diagnosis of multiple myeloma. Histopathologic studies of patients 
with retinopathy in the setting of multiple myeloma demonstrate a variety 
of abnormalities, including dilation and occlusion of retinal veins, retinal 
hemorrhages, exudates, microaneurysms, microthrombi in small retinal 
vessels, serous detachment of the neurosensory retina, and detachment of 
the RPE. These changes are not specific for multiple myeloma; however, 
they also occur in patients with hyperviscosity syndromes from other 
causes 
 
Opportunistic infections: 
 Opportunistic infections are common in immunosuppressed 
patients. Cytomegalovirus (CMV) is one of the most common causes of 
infectious retinitis in patients with altered immune status. The various 
herpesviruses can cause infectious retinitis as well. An unusual case of 
mumps uveitis in a patient with acute lymphocytic leukemia has been 
reported. Among parasitic infections, ocular toxoplasmosis is the most 
common. Fungal intraocular involvement is a frequent and severe 
problem. 
A patient with Hodgkin's disease with widespread severe 
destruction of the sensory retina was due to disseminated herpes zoster 
infection and viral retinitis of this type is known to occur in 
immunocompromised hosts. 
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Opportunistic infections are common in patients with Hodgkin's 
lymphoma. Toxoplasmic uveitis and chorioretinitis, Nocardia infection, 
and virtually all viral infections of the herpes family are known to occur. 
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AIM OF THE STUDY 
 
¾ To study the incidence of ophthalmologic manifestations in 
hematological malignancies 
¾ To study the types of clinical manifestations in hematological 
malignancies 
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                            MATERIALS AND METHODS                                          
 
¾ The study was conducted at Government Rajaji Hospital, madurai 
for a period of 18 months from February ’07 to August ‘08 
¾ The following patients were selected for this study: 
9 Patients with haematogenous malignancies including 
9 Leukemia’s- Acute myelogenous leukemia, chronic myelogenous 
leukemia, acute lymphocytic leukemia, chronic lymphocytic 
leukemia, hairy cell leukemia 
9 Multiple myeloma 
¾ The patients who were refered to ophthalmology op with 
haematological malignancies for ophthal evaluation. 
¾ Those patients with haematologic malignancies registered in the 
oncology department. 
¾ Paediatric patients with haematologic malignancies 
¾ The patients were graded according to  
9 Age  
9 Sex 
9 Duration after diagnosis of malignancy 
9 Type of ophthalmic manifestation 
9 Visual acuity at the time of presentation 
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¾ All patients were subjected to detailed ophthalmologic examination 
including visual acuity, external ocular examination, slit lamp 
examination and schiotz tonometry. The pupil was dilated with 1% 
tropicamide eye drops and detailed fundus examination with both 
direct and indirect ophthalmoscopy was done. Fundus photography 
was done for selected cases. Blood smear investigations were done 
for all the patients to diagnose the type of hematological 
malignancy. Bone marrow examination was also done for selected 
patients. 
¾ Those patients with haematological non-malignant condition were 
excluded from this study.  
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                                    OBSERVATION 
 
Out of the fifty patients with hematological malignancy, 22 patients were 
found to have ocular features. 
 
AGE INCIDENCE: 
In this study, age of the patient’s with hematological malignancy 
varied from 2 yrs to 72 yrs, and the ocular features also presented in a 
wide range of age group. 
Age (in yrs) No: of patients Ocular features 
0-9 6 6 
10-19 8 3 
20-29 9 5 
30-39 10 2 
40-49 10 3 
50-59 4 0 
60-69 2 2 
70-79 1 1 
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Among those patients with ocular features, the posterior segment 
findings were predominant among all age groups than the anterior 
segment involvement. 
 
Age (in yrs) Ocular features Anterior 
Segment 
Posterior 
Segment 
0-9 6 1 5 
10-19 3 1 2 
20-29 5 2 3 
30-39 2 1 1 
40-49 3 2 3 
50-59 0 0 0 
60-69 2 1 1 
70-79 1 0 1 
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SEX INCIDENCE: 
There were totally fifty patients included in this study. Out of the fifty 
patients included in this study, 32 were males and18 were females. Out of 
the 32 males, 16 had ocular findings, and 7 out of 18 females had ocular 
features.  
 Males Females 
Total cases 32 18 
Ocular features 16 7 
Anterior segment 
features 
2 1 
Posterior segment 
features 
12 4 
Neurological findings 3 2 
 
Among the ocular features, anterior segment findings were present 
in 2 males and 1 female. Neurological involvement was in 3 males and 2 
females. Posterior segment findings were present in 11 males and 4 
females, showing that posterior segment involvement were more common 
than anterior segment or neurological involvement.  
47 
 
INCIDENCE OF OCULAR FEATURES AMONG 
INDIVIDUAL DISEASES: 
Among all the individual hematological malignancies, Chronic 
Myeloid Leukemia presented with maximum of 75% incidence of ocular 
features, followed in equal frequency of both ALL and AML, about 
66.6% each. The least in the order was Hodgkin’s disease of 11.1%. In 
between were multiple myeloma of 45.4%,Non-Hodgkin’s disease 28.5% 
and CLL 25%. 
 
Type of disease Total cases Ocular 
features 
Percentage 
HD 9 2 22.2 
CLL 4 1 25 
NHL 7 2 28.5 
MM 11 5 45.4 
AML 6 4 66.6 
ALL 9 6 66.6 
CML 4 3 75 
  
The incidence of Posterior segment findings were more in each of 
the individual diseases over the anterior segment findings, except AML 
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which had an equal incidence and CML were in there were 2 cases with 
anterior segment findings and only one with posterior segment findings. 
Type of disease Ocular features Anterior 
Segment 
Posterior 
Segment 
NHL 2 0 2 
HD 2 1 2 
MM 5 2 3 
CML 3 2 1 
CLL 1 0 1 
AML 4 2 2 
ALL 6 1 5 
 
DIFFERENT TYPES OF OCULAR MANIFESTATIONS: 
Among the different types of ocular manifestations, posterior 
segment findings had a greater incidence with equal dominance of retinal 
and pre-retinal hemorrhages of 4 cases each. Followed next in frequency 
was Roth spots and nerve palsies including 3rd and 6th nerve palsies with 
ptosis and diplopia of 3 cases each. Next in order was vitreous 
hemorrhage and posterior uveitis with 2 cases each. All the rest of the 
features like proptosis, sub-retinal haemorrhages, anterior uveitis, 
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papilledema, sclerokeratitis, retinal detachment and dry eye were present 
in 1 case each. 
Ocular manifestation No: of cases Percentage 
RH 4 16 
PRH 4 16 
RS 3 12 
NP 4 16 
VH 2 8 
PU 2 8 
Proptosis 2 8 
AU 1 4 
SRH 1 4 
Papilledema 1 4 
RD 2 8 
Scerokeratitis 1 4 
Dry eye 1 4 
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VISUAL ACUITY AT THE TIME OF PRESENTATION: 
About 42 eyes of 26 patients had a fairly good visual acuity of 
about 6/6 – 6/9. 22 eyes of 17 patients had a visual acuity of 6/12 – 6/18 
and 21 eyes of 15 patients 6/24 – 6/36 respectively. Remaining 15 eyes of 
11 patients had an acuity ranging from 6/60 to PL+. T One patient with 
Hodgkins lymphoma who presented with RE-axial proptosis with 
cavernous sinus infiltration with total retinal detachment had no 
perception of light. 
There was a 21/2 yrs old male child who presented with axial 
proptosis of his right eye, had a poor visual acuity of perception of light. 
Another 2 yrs old male child with RE-vitreous haemorrhage and LE-RD 
with subretinal hemorrhage had an acuity of CFCF in his RE and HM in 
his LE. 
                                              
 
 
Visual Acuity No: of eyes Percentage 
6/6-6/9 42 42 
6/12- 6/18 22 22 
6/24- 6/36 21 21 
6/60 or < 15 15 
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DISCUSSION 
 
With evolving diagnostic and therapeutic advances, the survival of 
patients with hematological malignancies has considerably improved. 
This has led to an increase in the variability of ocular presentations in the 
form of side effects of the treatment and the way relapses are being first 
identified as an ocular presentation. All hematological malignancies may 
involve many ocular tissues either by direct infiltration, hemorrhage, 
ischemia, or toxicity due to various chemotherapeutic agents. Ocular 
involvement may also be seen in graft-versus-host reaction in patients 
undergoing allogeneic bone marrow transplantation, or simply as 
increased susceptibility to infections as a result of immunosuppression 
that these patients had undergone. This can range from simple bacterial 
conjunctivitis to an endophthalmitis. These malignancies can present as 
pathology in the adnexae, conjunctiva, sclera, cornea, anterior chamber, 
iris, lens, vitreous, retina, choroid, and optic nerve. Recognition of the 
varied ocular presentations is also important in assessing the course and 
prognosis of the disease (23). 
Osama Badeeb et al reported that Leukemia may affect any ocular 
tissue at some time during its course. The incidence of ocular 
involvement may be as high as 90%. Elise Torczynski et al. had reported 
primary ophthalmic leukemia infiltrate in 3% and secondary ophthalmic 
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findings in 39% and ocular changes unrelated to leukemia in 20% of their 
patients.  Acute leukemias affect the eye four times as frequently as the 
chronic types (9). 
 The retina is the most common ocular tissue to be involved in 
leukemia; Duke-Elder suggests that up to 90% of patients will develop 
retinopathy at some stage of their disease 
 On histopathological examination, the choroid is the most common 
ocular tissue to be involved in leukemia (85%) but this is rarely visible 
clinically. 
 The optic nerve is affected in 34% of the cases and the iris and 
anterior segments are affected in 0.5% to 2.6. This study showed that 17 
(54.8%) of the 31 leukemia patients had ocular abnormalities related to 
leukemia  
In a study by Schachat et al, it was reported that Leukemic 
infiltrates were present in 3% of patients, other findings related to 
leukemia were seen in 39% of patients, and 20% of patients had unrelated 
abnormalities. Visual loss was seen in at least 5% of the patients (24) 
 
AGE INCIDENCE: 
In this study out of 50 patients, 6 were in the age group of 0-9 
years (12%); 8 patients were in the age group of 10-19 yrs(16%); 9 
patients were in the age group of 20-29yrs(18%); 10 each  were in the age 
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group of 30-39 yrs and  40-49 yrs (20%); 4 patients in the age group of 
50-59 yrs(8%); 2 patients in the age group of 60-69 yrs(4%) and 1 patient 
in the age group of 70-79 yrs(2%); 
In this study the ocular features were present in the age group 
between 2 to 72 yrs. The youngest person was 2 yrs old. Moll et al in a 
Polish article studied children in the age group between 0.5 -17 yrs 
revealing ocular manifestations in 54% of their study group (8). 
In this study the ocular features involved both the anterior segment 
and the posterior segment of the eye. Predominantly anterior segment 
findings were found only in 1 case of each age group with a maximum of 
2 in the age group between 20-29 yrs and 40-49 yrs. The posterior 
segment findings were predominant in all the age groups with a 
maximum of 5 in the age group between 0-9 yrs. Only those patients in 
the age group between 50-59 yrs had no patients with either anterior or 
posterior segment findings. 
Osama Badeeb et al reported a study in which patients with 
leukemia ranged from 0.8 to 70 years with a median of 12.5 years.  The 
interval between the diagnosis of leukemia and the first ocular 
manifestation was ≤six months in 11 patients and 24 to 60 months in six 
patients. In this study the lowest interval between the diagnosis of 
malignancy and the first ocular manifestation was 1 month reported in 3 
patients(9). 
54 
 
Eight patients with mean age of 61.25 years (range 42-78) who 
exhibited ophthalmic manifestations of multiple myeloma were studied 
by Shirley Fung et al, in which they found that 50% of their patients had 
neuro-ophthalmic symptoms and 37.5% presented with orbital 
involvement. 
In a study by Reddy et al they reported that the eye changes were 
seen more often in adults (49.1%) than in children (16.5%). In this study 
also the ocular manifestations were more common in adults (59.09%) 
than in children (40.91%) (25). 
 
SEX INCIDENCE: 
In this study out of the 50 patients 32 were males (64%) and 18 
were females (36%). Of   the 32 males, in the 16patients who had ocular 
features, around 12 patients had predominantly posterior segment 
findings. 2 patients had anterior segment features and 3 with neurologic 
findings. Of the 18 females, in the 7 patients who had ocular features, a 
maximum of 4 patients presented with posterior segment features and 1 
patient had anterior segment feature. 2 patients had neurological findings. 
In this study, ocular manifestations were more common in males (50%) 
than in the females (38.9%). And in both the sex groups, the posterior 
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segment features were predominating. This difference follows the higher 
incidence of haematological malignancies in males. 
 
INCIDENCE OF OCULAR FEATURES AMONG 
VARIOUS DISEASES: 
Out of the 50 patients in the study group 7 patients had Non-
Hodgkins lymphoma with 2 patients with ocular features (28.6%). 
Hodgkins disease was present in 9 patients with only 2 patient having 
ocular manifestation (22.2%).  5 out of the 11 patients with multiple 
myeloma had ocular features (45.5%). Chronic myeloid leukemia was 
present in 4 patients, out of which 3 patients had ocular features (75%). 
Chronic lymphoid leukemia was present in 4 patients with only 1 patient 
having ocular signs (25%). Acute lymphatic leukemia was present in 9 
patients with 6 patients having ocular signs (66.6%) and acute myeloid 
leukemia in 6 patients with 4 patients having ocular manifestations 
(66.6%). 
Moll et al in a study of 39 children (age 0.5-17 years) with 
leukemia or lymphoma, reported that ocular manifestations were present 
in 54% of study group (21 children) (8) 
Shirley Fung et al in a study of 8 patient, six patients (75%) had 
known MM at the time of their ophthalmic evaluation, reported that 
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ophthalmic manifestations of MM are uncommon and diverse. They may 
appear at the initial presentation of the disease or occur late in the disease 
process (21). 
Osama badeeb et al studied 31 leukemic patients of which 17 
(54.8%) patients had ocular abnormalities related to leukemia. Most 
ocular changes occurred in the acute forms of leukemia as previously 
reported. This is because the acute forms of leukemia are the most 
common and involve the CNS more frequently than do the chronic forms 
(9). Which is comparable to the present study which also shows more 
incidence of ocular features in acute (66.6%) than in chronic 
malignancies(50%). 
Schachat et al in their study had reported primary ophthalmic 
leukemia infiltrate in 3% and secondary ophthalmic findings in 39% and 
ocular changes unrelated to leukemia in 20% of their patients (24). 
 
DIFFERENT TYPES OF OCULAR MANIFESTATIONS: 
The various ocular manifestations of hematological malignancies 
can be broadly divided into anterior segment and posterior segment 
findings. In this study, among all the diseases the posterior segment 
findings were predominating including the retinal and pre-retinal 
hemorrhages, vitreous hemorrhage, Roth spots, sub-retinal hemorrhages, 
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papilledema, retinal detachment and posterior uveitis, constituting about 
72% of the ocular manifestations.  
The anterior segment findings were dry eye, sclerokeratitis, 
anterior uveitis constituting 12% pf the ocular manifestations; and 
neurological manifestations were nerve palsies and proptosis, forming 5 
cases of the total about 16%. 
Moll A et al in their study found that the most frequent ocular 
findings were seen in conjunctiva (33.4%). 15.4% patients presented with 
posterior segment findings, without loss of ocular acuity. Other 
manifestations were dry eye syndrome and proptosis(8). 
Osama badeeb et al in their study found that ocular manifestations 
could be related to direct infiltration of the eye by leukemic cells, or 
secondary to anemia, hyperviscosity, increased intracranial pressure, 
pancyto-penia and treatment with irradiation or chemotherapy. Primary 
leukemic infiltrate was observed in 14 (45.2%) of the ocular relapses in 
the form of Anterior segment leukemic infiltrate(ASLI), optic nerve and 
ciliary body infiltrate, glaucoma, proptosis, choroidal and retinal 
detachment. Most ocular changes occurred in the acute forms of 
leukemia. This is because the acute forms of leukemia are the most 
common and involve the CNS more frequently than do the chronic forms 
(9). In contrary to this study they observed that the anterior segment of 
the eye was commonly involved in their study. 
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They also found that the optic nerve was involved in nine of the 
leukemic relapses, most often while the patients were in CNS relapse.  
Leukemic infiltrate of the optic nerve, in contrast to papilledema, is often 
unilateral.  When it occurs bilaterally, however, it may be difficult to 
differentiate clinically from papilledema. .  In papilledema secondary to 
increased intracranial pressure due to CNS leukemic infiltration, there 
was dilatation of the brain ventricles, swollen sheath, tortuous optic 
nerves and engorged orbital vessels.  Orbital CT scan was found to be 
useful in confirming retrobulbar optic nerve infiltrate.  The conjunctival 
involvement was secondary to thrombocytopenia. Cranial nerve palsy 
secondary to CNS infiltrate in 3 patients. Two of their patients who had 
ALL developed proptosis(9). In the present study there is one case of 
papilledma, but no case of optic nerve infiltration. 
Cysts of the ciliary body and retinal vascular lesions represent the 
most common ocular manifestations in myeloma patients. Paris et al 
reported a case of anterior chamber infiltration–simulating hypopyon 
(pseudohypopyon) in multiple myeloma(10). Matano et al reported a 
patient with AML who developed leukemic hypopyon(33). David et al 
reported a treatment-resistant unilateral hypopyon in the remission phase 
of ALL(42). 
Saenz frances et al reported a case of bilateral papilledema 
secondary to chronic lymphocytic leukemia. In this study there was just 
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one patient with bilateral established papilledema in a case of acute 
myeloid leukemia (11). 
In this study there was a case of anterior uvieits that occurred in a 
case of acute lymphoblastic leukemia. Similiarly Elise Torczynski et al 
reported a case of anterior uveitis occurring in acute lymphoblastic 
leukemia (27). Atchaneeyasakul et al reported a case of relapsing ALL 
ahich presented as anterior uveitis (34). Molina Garrido et al reported a 
B-cell lymphochytic lymphoma, which presented as bilateral posterior 
uveitis (35). 
Francois Thoumazet et al reported 2 cases of multiple myeloma 
presenting with orbit and muscle involvement and distal bony erosion 
(20). Shimada et al reported a case of bilateral optic neuropathy 
associated with multiple myeloma(13).  
Rosenthal AR reported that retinal microaneurysms, capillary 
closure, and neovascularization have been documented in individuals 
with chronic leukemia. Optic nerve, choroid and iris infiltration can also 
occur (28). 
In this study there were 11 patients with multiplemyeloma of 
which 5 had varying ocular features like sclerokeratitis, vitritis, pre-
retinal hemorrhages, vitreous haemorrhage and 6th nerve palsy. Shirley 
fung reported that in a study among 8 patients of multiple myeloma, four 
patients (50%) had neuro-ophthalmic manifestations resulting in diplopia 
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or visual disturbances. Three patients (37.5%) presented with orbital 
involvement and 1 (12.5%) with hyperviscosity retinopathy. Five patients 
(62.5%) died within 2 months of their ophthalmic presentation. And those 
ophthalmic manifestations of Multiple Myeloma are uncommon and 
diverse. They may appear at the initial presentation of the disease or 
occur late in the disease process (21). Shakin EP et al reported a case of 
infiltration of the iris that simulated a nongranulomatous uveitis (39). 
Kazuhiro Yamada et al reported a case of primary B-cell non-Hodgkins 
lymphoma with anterior uveitis resulting from primary malignant 
lymphoma in the iris (41) 
 Pradhan S et al reported a case of Multiple myeloma with bilateral 
tearing secondary to infiltrative lesions of the lacrimal sacs (40). 
Fackler et al reported a case of acute lymphoblastic leukemia 
presenting as bilateral serous macular detachments (16). 
In this study there was a patient with ALL who presented with 
unilateral rhegmatogenous retinal detachment. B. A.  Michael.S.Peterson 
et al report unusual retinal manifestation of intraocular lymphoma 
secondary to systemic non-Hodgkins’ lymphoma. Ocular inflammation is 
common with these tumors and presents a diagnostic challenge to 
clinicians who discover assumed idiopathic uveitis in older patients 
which is refractory to steroid treatment (29). 
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T-cell lymphomas are a type of non-hodgkin’s lymphoma in which 
ophthalmic manifestations are very rare. Only a total of 20 cases have 
been reported and about half in association with mycoses fungoides. A 
case with intra-ocular metastases to the Iris and ciliary body which 
presented as granulomatous iritis was reported by Ove.A.Jensen et al 
(30). 
Glavici.M reported a case of iridic nodular lesion which had 
appeared in the evolution of a non-Hodgkin malignant lymphoma in a 8-
year old boy (31). Non-Hodgkin's lymphomas can simulate uveitis (32). 
Werschnik C et al described a patient with tumor of the optic disk in one 
eye and bilateral uveitis with secondary glaucoma (36). 
Neuro-ophthalmological complications of lymphoma are numerous 
and occur mostly in the setting of a known lymphoma or as the sign of a 
recurrence. Henchoz L et al has described a case of simultaneous bilateral 
optic neuropathy as the initial clinical manifestation of a non-Hodgkin 
malignant lymphoma (37). There is also a report of a bilateral uveitis and 
marked bilateral nonrhegmatogenous retinal detachment near the optic 
disk occurring in a case of B-cell derived type of non-hodgkins 
lymphoma reported by Kormann BA et al(38). 
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CORRELATION OF VISUAL ACUITY AT THE TIME 
OF PRESENTATION: 
In this study almost 42% of the patients who presented to us with 
hematological malignancies had a vision of around 6/6 – 6/9. 22% of the 
patients had 6/12 – 6/18 vision. About 21% of them had 6/24 – 6/36. 15% 
of the patients had a vision of 6/60 or worse. In this study the poor vision 
is attributed to pre-retinal haemorrhage at the macula, vitritis, axial 
proptosis, vitreous haemorrhage, retinal detachment, cavernous sinus 
infiltration and sixth nerve palsy. 
Hendrik AM et al found that a number of ocular problems 
compromising vision occurred in a patient with chronic myeloid leukemia 
following blastic transformation. Hemorrhagic retinopathy developed 
with systemic relapse and resolved with control of systemic disease. 
Optic nerve involvement occurred with meningeal leukemia. bilateral 
vitreous hemorrhages occurred, severely impairing vision. Leukemic 
infiltration of the eye may occur with increasing frequency in CML as the 
survival following bastic transformation improves. Infiltration should be 
recognized and treated promptly if serious loss of vision is to be avoided 
(26).                                       
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CONCLUSION 
¾ Ophthalmic manifestations of haematologic malignancies are more 
common in the age group between 0-9 yrs (100%); Next common 
age group is 20-29 yrs (55%). 
¾ The posterior segment findings were predominant in all the age 
groups with a maximum of 5 in the age group between 0-9 yrs. 
¾ The ocular features in cases of haematologic malignancies are 
more common in the males (64%) 
¾ Eye findings were more prevalent in the leukemia’s than in 
lymphomas and multiple myeloma. 
¾ Eye findings were more commonly seen in acute than in chronic 
malignancies 
¾ Amongst the individual diseases, chronic myeloid leukemia had a 
maximum incidence of ophthalmic manifestations (75%). 
¾ Among the different types of manifestations, the posterior segment 
manifestations were predominating in most of the age groups and 
in most of the individual disease entities. 
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¾ Among the various types of posterior segment manifestations, 
retinal haemorrhage, pre-retinal haemorrhage and roth spots 
predominated. The neurological involvement in the form nerve 
palsies also contributed significantly. 
¾ Regarding the visual acuity at the time of presentation of the ocular 
features, most of the patients had a good acuity of 6/6-6/9 in 43%.  
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                                PROFORMA 
NAME 
AGE 
SEX 
IP/OP NO: 
ADRESS: 
 
C/O Defective vision/ blurred vision                                
Duration 
          Loss of vision 
         Headache/ Polyuria/ Haematuria 
          Vomitting/Haematemesis/Haemoptysis 
          Floaters 
          Giddiness/Chest pain/ Palpitation 
         Fever 
          Photophobia 
Treatment History: Duration of malignancy 
                               H/O Drug intake- yes/no- specify  
                               Duration 
                               Regular/irregular 
                               Symptomatic relief- adequate/ not adequate 
                               H/o discontinuation of drugs 
Past History: 
Initial symptoms that lead to the diagnosis of the disease 
H/O Hypertension/Diabetes/ Stroke/ Myocardial infarction/Peptic ulcer/ 
Ischemic heart disease 
 
Family History: 
H/O similar illness in the other family members 
 
                                         EXAMINATION 
 
GENERAL EXAMINATION 
General Condition- good/fair/poor 
CVS- 
RS- 
CNS- 
Abdomen- 
Pulse rate- 
Blood Pressure- 
Cyanosis/ Pallor/ Icterus/ Clubbing/ Pedal edema 
 
  
OPHTHALMIC EXAMINATION: 
 
Facial Asymmetry- yes/no 
Head posture-Normal/Abnormal 
Local Examination: 
 
               Left Eye                                                                       Right Eye 
                                                            Lids 
                                                            Conjunctiva 
                                                            Cornea 
                                                            Anterior chamber 
                                                            Iris 
                                                            Pupil 
                                                            Lens 
                                                            EOM 
 
Vision 
 
Tension 
 
Gonioscopy 
 
Fundus: 
 
Direct Ophthalmoscopy 
 
Indirect Ophthalmoscopy 
 
INVESTIGATIONS 
Haemoglobin 
Blood sugar 
Urea  
Creatinine  
Blood smear 
Total count 
Differential count 
Erythrocyte sedimentation rate 
X-Ray Chest PA view 
ECG in all leads 
Bone marrow smear 
Fundus flurescein angiography 
USG B-Scan 
 CML Chronic Myeloid Leukemia 
 
CLL Chronic Lymphoid Leukemia 
 
MM Multiple Myeloma 
 
CFCF Counting Fingers Close to Face 
 
HM Hand Movements 
 
PL Perception of Light  
 
 
 
 
 
 
 
 
 
 
